For example, a poor response to the thalidomide-based immunomodulatory drugs (IMiDs) in multiple myeloma (MM) patients has been linked to their low expression of CRBN although higher expression of CRBN is usually found in cancer cell lines from hematological tumors compared to solid cancers [52,53]. Here, CRBN is linked to plasma cell myeloma.